Alphamab Oncology 2025 SR
The report highlights Alphamab Oncology's sustainability progress in 2025, focusing on innovative oncology biopharmaceuticals and robust ESG governance. The company advanced its clinical pipeline, including the world's first subcutaneously injectable PD-(L)1 inhibitor, Envafolimab, and expanded its R&D capabilities with a new payload discovery platform. Environmentally, Alphamab transitioned to municipal steam, eliminating direct boiler emissions, and achieved a 20.55% reduction in water consumption intensity. Socially, the company maintained a diverse workforce with 33.3% female board representation and provided free patient assistance to nearly 80,000 patients cumulatively.
Company: Alphamab Oncology
Sector: Manufacturing
Country: China
Year: 2025
Type: SR
Pages: 53
Back to company
Alphamab Oncology
Environmental, Social And Governance Report
The report highlights Alphamab Oncology's sustainability progress in 2025, focusing on innovative oncology biopharmaceuticals and robust ESG governance. The company advanced its clinical pipeline, including the world's first subcutaneously injectable PD-(L)1 inhibitor, Envafolimab, and expanded its R&D capabilities with a new payload discovery platform. Environmentally, Alphamab transitioned to municipal steam, eliminating direct boiler emissions, and achieved a 20.55% reduction in water consumption intensity. Socially, the company maintained a diverse workforce with 33.3% female board representation and provided free patient assistance to nearly 80,000 patients cumulatively.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees